Synlogic Investor Relations Material
Latest events
Q2 2022
Synlogic
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Synlogic Inc
Access all reports
Synlogic, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases. Synlogic’s product candidates include SL-401, which is a drug candidate for the treatment of Type 1 Diabetes Mellitus, a rare metabolic disease; SL-701, which is an orally administered synthetic biotic therapeutic designed to regulate the gut microbiome to protect against Clostridium difficile infection; and SL-701 as a treatment for Multiple Sclerosis.
Latest articles
Remembering Daniel Kahneman: Transforming Psychology and Economics
Explore Daniel Kahneman's legacy in psychology and economics, highlighting his impact on decision-making and behavioral economics.
28 Mar 2024
Deere & Company: Shaping Agriculture & Construction Since 1837
Exploring Deere & Company: A global leader in agriculture & construction equipment since 1837.
28 Mar 2024
Jane Fraser: First Female Leader of a Major Wall Street Bank
Discover the journey of Jane Fraser, CEO of Citigroup and the first female leader of a major Wall Street bank.
28 Mar 2024
Ticker symbol
Country
🇺🇸 United States